COMPARISON OF EFFICACY OF HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPEUTICS MITOMYCIN C VERSUS OXALIPLATIN IN EXPERIMENTAL COLORECTAL PERITONEAL METASTASIS MODEL

被引:0
|
作者
Manoglu, Berke [1 ]
Canda, Aras Emre [3 ]
Yavuzsen, Tugba [2 ]
Aktas, Safiye [3 ]
Altun, Zekiye [3 ]
Yilmaz, Osman [4 ]
Bisgin, Tayfun [1 ]
机构
[1] Dokuz Eylul Univ, Fac Med, Dept Gen Surg, Izmir, Turkiye
[2] Dokuz Eylul Univ, Fac Med, Dept Clin Oncol, Izmir, Turkiye
[3] Dokuz Eylul Univ, Inst Oncol, Dept Basic Oncol, Izmir, Turkiye
[4] Dokuz Eylul Univ, Fac Med, Dept Lab Anim Sci, Izmir, Turkiye
来源
JOURNAL OF BASIC AND CLINICAL HEALTH SCIENCES | 2024年 / 8卷 / 01期
关键词
peritoneal metastasis model; colorectal cancer; HIPEC; CYTOREDUCTIVE SURGERY; AMERICAN SOCIETY; CARCINOMATOSIS; CANCER; MALIGNANCIES; THERAPY; HIPEC;
D O I
10.30621/jbachs.1339735
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Aim: Our study aimed to establish a mouse model with colorectal cancer -induced peritoneal metastasis(PM) and to compare the efficacy of hyperthermic intraperitoneal chemotherapeutic agents, mitomycin C and oxaliplatin. Materials and Methods: The peritoneal metastasis model was established in nude mice using the CC531 colon carcinoma cell line. Models with PM were randomized into four groups of seven animals each: Group -1, control group; Group -2, hyperthermic intraperitoneal chemotherapy(HIPEC) with mitomycin C(MMC), and Group -3, HIPEC with Oxaliplatin(OXA). Results: Tumor development was achieved in all animals. While the tumor burden decreased significantly in the treatment Group -2(p=.013). In the PM mouse model, hyperthermic intraperitoneal administration of MMC had a higher tumoricidal effect than hyperthermic intraperitoneal administration of OXA. Conclusions: Our PM model provided a good opportunity to examine the efficacy of HIPEC and IPIP. Hyperethermic intraperitoneal mitomycin applied in the colorectal PM animal model was found to have higher tumoricidal activity than oxaliplatin. In future studies, we plan to evaluate efficacies of different drugs in the PM models we have created.
引用
收藏
页码:181 / 191
页数:11
相关论文
共 50 条
  • [1] Investigation of the effectiveness of hyperthermic intraperitoneal chemotherapy in experimental colorectal peritoneal metastasis model
    Manoglu, Berke
    Yavuzsen, Tugba
    Aktas, Safiye
    Altun, Zekiye
    Yilmaz, Osman
    Gokbayrak, Ozde Elif
    Erol, Aylin
    PLEURA AND PERITONEUM, 2023, 8 (03) : 123 - 131
  • [2] Elevated temperatures and longer durations improve the efficacy of oxaliplatin- and mitomycin C-based hyperthermic intraperitoneal chemotherapy in a confirmed rat model for peritoneal metastasis of colorectal cancer origin
    Helderman, Roxan F. C. P. A.
    Bokan, Bella
    van Bochove, Gregor G. W.
    Rodermond, Hans M.
    Thijssen, Elsy
    Marchal, Wouter
    Torang, Arezo
    Loke, Daan R.
    Franken, Nicolaas A. P.
    Kok, H. Petra
    Tanis, Pieter J.
    Crezee, Johannes
    Oei, Arlene L.
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [3] Hyperthermic Intraperitoneal Chemotherapy with Mitomycin C versus Oxaliplatin after Cytoreductive Surgery for the Treatment of Peritoneal Metastases of Colorectal Cancer Origin
    Papageorgopoulou, Chrysanthi
    Nikolakopoulos, Konstantinos
    Seretis, Charalampos
    CHIRURGIA, 2022, 117 (03) : 266 - 277
  • [4] Hyperthermic intraperitoneal chemotherapy using a combination of mitomycin C,5-fluorouracil, and oxaliplatin in patients at high risk of colorectal peritoneal metastasis: A Phase I clinical study
    Shimizu, T.
    Sonoda, H.
    Murata, S.
    Takebayashi, K.
    Ohta, H.
    Miyake, T.
    Mekata, E.
    Shiomi, H.
    Naka, S.
    Tani, T.
    EJSO, 2014, 40 (05): : 521 - 528
  • [5] Optimal perfusion chemotherapy: A prospective comparison of mitomycin C and oxaliplatin for hyperthermic intraperitoneal chemotherapy in metastatic colon cancer
    Woeste, Matthew R.
    Philips, Prejesh
    Egger, Michael E.
    Scoggins, Charles R.
    McMasters, Kelly M.
    Martin, Robert C. G.
    JOURNAL OF SURGICAL ONCOLOGY, 2020, 121 (08) : 1298 - 1305
  • [6] Systematic review of published literature on oxaliplatin and mitomycin C as chemotherapeutic agents for hyperthermic intraperitoneal chemotherapy in patients with peritoneal metastases from colorectal cancer
    Wisselink, Daan D.
    Braakhuis, Linde L. F.
    Gallo, Gaetano
    van Grevenstein, Wilhelmina M. U.
    van Dieren, Susan
    Kok, Niels F. M.
    de Reuver, Philip R.
    Tanis, Pieter J.
    de Hingh, Ignace H. J. T.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 142 : 119 - 129
  • [7] A set of molecular markers predicts chemosensitivity to Mitomycin-C following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis
    Shannon, Nicholas Brian
    Tan, Joey Wee-Shan
    Tan, Hwee Leong
    Wang, Weining
    Chen, Yudong
    Lim, Hui Jun
    Tan, Qiu Xuan
    Hendrikson, Josephine
    Ng, Wai Har
    Loo, LiYang
    Skanthakumar, Thakshayeni
    Wasudevan, Seettha D.
    Kon, Oi Lian
    Lim, Tony Kiat Hon
    Tan, Grace Hwei Ching
    Chia, Claramae Shulyn
    Soo, Khee Chee
    Ong, Chin-Ann Johnny
    Teo, Melissa Ching Ching
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [8] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis : Higher complication rate for oxaliplatin compared to mitomycin C
    Rouers, A.
    Laurent, S.
    Detroz, B.
    Meurisse, M.
    ACTA CHIRURGICA BELGICA, 2006, 106 (03) : 302 - 306
  • [9] Identification of pharmacogenetic biomarkers for efficacy of cytoreductive surgery plus hyperthermic intraperitoneal mitomycin C in patients with colorectal peritoneal metastases
    Hulshof, E. C.
    Lurvink, R. J.
    Caserta, N.
    de Hingh, I. H. J. T.
    van Wezel, T.
    Bohringer, S.
    Swen, J. J.
    Gelderblom, H.
    Guchelaar, H. J.
    Deenen, M. J.
    EJSO, 2020, 46 (10): : 1925 - 1931
  • [10] Intraperitoneal hyperthermic perfusion with mitomycin C for colorectal cancer with peritoneal metastases
    Schneebaum, S
    Arnold, MW
    Staubus, A
    Young, DC
    Dumond, D
    Martin, EW
    ANNALS OF SURGICAL ONCOLOGY, 1996, 3 (01) : 44 - 50